冠昊生物(300238.SZ)子公司北京文豐天濟擬實施股權激勵方案
格隆匯12月26日丨冠昊生物(300238.SZ)公佈，公司於2019年12月26日召開第四屆董事會第十九次會議，審議通過了《關於控股子公司擬實施股權激勵暨股權轉讓的議案》，同意公司控股子公司北京文豐天濟醫藥科技有限公司實施股權激勵方案。
公司控股子公司北京文豐天濟醫藥科技有限公司(“北京文豐天濟”)為充分調動其經營管理層及核心員工的積極性，穩定和吸引人才，達到企業與員工的雙贏，於2016年11月28日製定《北京文豐天濟醫藥科技有限公司股權激勵方案》(“激勵方案”)，根據激勵方案約定，北京文豐天濟各股東按所持股權比例拿出北京文豐天濟總股份的15%無償用於員工股權激勵，激勵對象達到預定目標將按照20%、20%和60%比例授予相應股權。根據預定目標完成情況，北京文豐天濟各股東已於2016年底向核心管理人員和業務骨幹實施20%比例(即北京文豐天濟總股份的3%)的股權激勵。
截至目前，根據激勵方案的設定目標，北京文豐天濟已完成本維莫德的所有註冊和產業化工作，將授予剩餘80%比例中的部分股權激勵，擬通過員工持股平台珠海合濟中康醫藥合夥企業(普通合夥)(“合濟中康”)持有激勵股權。此次股權激勵將採用股權轉讓的方式實施，冠昊生物將其持有的北京文豐天濟5.1744%股權無償轉讓給合濟中康，廣東中昊藥業有限公司(“廣東中昊”)將進行同股權比例轉讓。此次股權激勵完成後，公司持有北京文豐天濟和廣東中昊的股權比例將由58.20%變為53.0256%。
此次北京文豐天濟實施股權激勵是對其2016年制定的激勵方案的執行，表明該激勵方案充分調動了北京文豐天濟經營管理層及核心員工的積極性，對於穩定和吸引人才起到積極作用，有利於公司實現可持續發展。
此次股權激勵完成後，公司持有的北京文豐天濟58.20%股權和廣東中昊58.20%股權比例將分別變為53.0256%，預計將對北京文豐天濟和廣東中昊2019年度當期利潤造成一定影響。敬請廣大投資者謹慎決策，注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
